BridgeMD
New treatment option for Non-Alcoholic Fatty Liver Disease
Official title The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
ClinicalTrials.gov ID: NCT06717828
What this study is testing
- What it's testing
- Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma. It is also implicated in the development of other metabolic dysfunction-related diseases.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 75
You may be able to join if
- Age between 40 and 75 years;
- Liver fat content measured by mDixon QUANT is ≥5%;
- Diagnosis of metabolic associated fatty liver disease;
- Overweight/obesity (BMI ≥ 24 kg/m²);
- Signed written informed consent.
You likely can't join if
- Excessive alcohol consumption (definition: in the past 6 months, males have consumed more than 140g of alcohol per week, and females have consumed...
- Fatty liver due to other causes: such as alcoholic fatty liver, acute and chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, etc.;
- Severe cardiovascular diseases, including myocardial infarction within the past 6 months;
- Heart failure (NYHA classification: III - IV);
- Biliary diseases: such as obstructive biliary diseases;
- Other diseases affecting glucose and lipid metabolism: diabetes, hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.;
See the full eligibility criteria
- Age between 40 and 75 years;
- Liver fat content measured by mDixon QUANT is ≥5%;
- Diagnosis of metabolic associated fatty liver disease;
- Overweight/obesity (BMI ≥ 24 kg/m²);
- Signed written informed consent.
- Excessive alcohol consumption (definition: in the past 6 months, males have consumed more than 140g of alcohol per week, and females have consumed more than 70g);
- Fatty liver due to other causes: such as alcoholic fatty liver, acute and chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, etc.;
- Severe cardiovascular diseases, including myocardial infarction within the past 6 months;
- Heart failure (NYHA classification: III - IV);
- Biliary diseases: such as obstructive biliary diseases;
- Other diseases affecting glucose and lipid metabolism: diabetes, hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.;
- Poorly controlled blood pressure: SBP ≥ 180 mmHg, DBP ≥ 100 mmHg;
- Chronic kidney disease or severe renal impairment, defined as serum creatinine of 135 µmol/L (1.5 mg/dL) for males and 110 µmol/L (1.3 mg/dL) for females;
- Patients unable to communicate normally, such as those with dementia or cognitive impairment;
- Currently pregnant or planning to become pregnant in the near future;
- Other conditions preventing participation in follow-up interventions;
- Other clinical diseases that make participation in exercise unsuitable, such as inability to cooperate with exercise therapy due to severe pain or joint deformities, or the use of medications that may interfere with the...
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.